🚀 VC round data is live in beta, check it out!
MDxHealth Valuation Multiples
Discover revenue and EBITDA valuation multiples for MDxHealth and similar public comparables like Fonar, Curasight, Scope Fluidics, Infinitt Healthcare and more.
MDxHealth Overview
About MDxHealth
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Founded
2003
HQ
Employees
312
Website
Financials (LTM)
EV
$175M
MDxHealth Financials
MDxHealth reported last 12-month revenue of $117M and EBITDA of $444K.
In the same LTM period, MDxHealth generated $75M in gross profit, $444K in EBITDA, and had net loss of ($30M).
Revenue (LTM)
MDxHealth P&L
In the most recent fiscal year, MDxHealth reported revenue of $108M and EBITDA of ($1M).
MDxHealth expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $117M | XXX | $108M | XXX | XXX | XXX |
| Gross Profit | $75M | XXX | $70M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $444K | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | (1%) | XXX | XXX | XXX |
| EBIT Margin | (10%) | XXX | (13%) | XXX | XXX | XXX |
| Net Profit | ($30M) | XXX | ($34M) | XXX | XXX | XXX |
| Net Margin | (26%) | XXX | (31%) | XXX | XXX | XXX |
| Net Debt | — | — | $47M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MDxHealth Stock Performance
MDxHealth has current market cap of $118M, and enterprise value of $175M.
Market Cap Evolution
MDxHealth's stock price is $2.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $175M | $118M | 0.0% | XXX | XXX | XXX | $-0.65 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMDxHealth Valuation Multiples
MDxHealth trades at 1.5x EV/Revenue multiple, and 394.6x EV/EBITDA.
EV / Revenue (LTM)
MDxHealth Financial Valuation Multiples
As of April 20, 2026, MDxHealth has market cap of $118M and EV of $175M.
Equity research analysts estimate MDxHealth's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MDxHealth has a P/E ratio of (3.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV (current) | $175M | XXX | $175M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 394.6x | XXX | (134.8x) | XXX | XXX | XXX |
| EV/EBIT | (14.9x) | XXX | (12.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.5x | XXX | XXX | XXX |
| P/E | (3.9x) | XXX | (3.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (52.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MDxHealth Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MDxHealth Margins & Growth Rates
MDxHealth's revenue in the last 12 month grew by 25%.
MDxHealth's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
MDxHealth's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MDxHealth's rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
MDxHealth Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Growth | 1981% | XXX | (449%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 38% | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 24% | XXX | 55% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MDxHealth Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MDxHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Fonar | XXX | XXX | XXX | XXX | XXX | XXX |
| Curasight | XXX | XXX | XXX | XXX | XXX | XXX |
| Scope Fluidics | XXX | XXX | XXX | XXX | XXX | XXX |
| Infinitt Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyperfine | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MDxHealth M&A Activity
MDxHealth acquired XXX companies to date.
Last acquisition by MDxHealth was on XXXXXXXX, XXXXX. MDxHealth acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MDxHealth
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMDxHealth Investment Activity
MDxHealth invested in XXX companies to date.
MDxHealth made its latest investment on XXXXXXXX, XXXXX. MDxHealth invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MDxHealth
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MDxHealth
| When was MDxHealth founded? | MDxHealth was founded in 2003. |
| Where is MDxHealth headquartered? | MDxHealth is headquartered in United States. |
| How many employees does MDxHealth have? | As of today, MDxHealth has over 312 employees. |
| Who is the CEO of MDxHealth? | MDxHealth's CEO is Michael K. McGarrity. |
| Is MDxHealth publicly listed? | Yes, MDxHealth is a public company listed on Nasdaq. |
| What is the stock symbol of MDxHealth? | MDxHealth trades under MDXH ticker. |
| When did MDxHealth go public? | MDxHealth went public in 2008. |
| Who are competitors of MDxHealth? | MDxHealth main competitors are Fonar, Curasight, Scope Fluidics, Infinitt Healthcare. |
| What is the current market cap of MDxHealth? | MDxHealth's current market cap is $118M. |
| What is the current revenue of MDxHealth? | MDxHealth's last 12 months revenue is $117M. |
| What is the current revenue growth of MDxHealth? | MDxHealth revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of MDxHealth? | Current revenue multiple of MDxHealth is 1.5x. |
| Is MDxHealth profitable? | Yes, MDxHealth is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MDxHealth? | MDxHealth's last 12 months EBITDA is $444K. |
| What is MDxHealth's EBITDA margin? | MDxHealth's last 12 months EBITDA margin is 0%. |
| What is the current EV/EBITDA multiple of MDxHealth? | Current EBITDA multiple of MDxHealth is 394.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.